Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,083 total articles
Beam Therapeutics Inc. CEO John M. Evans disposed of 50,000 shares of common stock on March 30 and 31, 2026, generating about $1.1 million at weighted average prices between $22.3692 and $22.7634. On the same dates he purchased 50,000 shares at $0.67 for $33,500 and acquired a further 90,000 shares at no cost. After these transactions Evans holds 1…
Former Meridian Holdings director and CEO Anthony Brian Goodman and the institutional group Luxor Capital LLC reported direct sales totaling $50,536 across two trading days in late March 2026. The transactions came amid recent company moves including a material debt reduction, a reverse stock split and corporate name change, and routine executive a…
Jacob Zabkowicz, chief executive of Hudson Talent Solutions LLC - a Star Equity Holdings subsidiary - purchased 150 shares of Star Equity Holdings, Inc. (NASDAQ:STRR) on March 31, 2026, at $10.61 per share, a transaction valued at $1,591. The purchase raises his direct holdings to 180,863 shares, comprising 135,456 restricted stock units and 45,407…
Star Equity Holdings Chief Executive Officer Jeffrey Eberwein disposed of 7,722 shares of Series A Preferred Stock on March 30, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $9.95 each for total proceeds of $76,833. After the sale Eberwein directly holds 764,217 shares of Star Equity Holding…
The Hershey Trust Co., acting as trustee for the Milton Hershey School, sold 29,000 shares of Hershey Co. (NASDAQ: HSY) common stock across March 30 to April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The disposals generated $6.26 million in proceeds, at prices between $200.7672 and $215.0655. Following the s…
PBF Energy Inc. Senior Vice President James E. Fedena sold 77,026 shares of Class A Common Stock on March 30 and 31, 2026, generating about $4.8 million. At the same time he exercised options to acquire 77,085 shares at strike prices ranging from $6.72 to $35.30, according to a Form 4 filing. The stock has been trading near its 52-week high amid a …
Christopher J. Joyce, Alignment Healthcare's chief legal and administrative officer, reported the sale of 18,013 shares on April 1, 2026, in a Form 4 filing. The disposals, executed at a weighted-average price of $17.7923, generated proceeds of $320,492. The transaction coincides with the company trading near $17.85, a year-to-date decline of 9.6%,…
PBF Energy director Thomas J. Nimbley sold 50,000 shares of the company’s Class A common stock on March 31, 2026, for $2.53 million and exercised 50,000 options the same day at a strike price of $28.67. The share sale came after a one-year gain of 149% and follows InvestingPro’s assessment that the stock is slightly overvalued relative to its Fair …
Frates Caton, Executive Vice President of Costco Wholesale Corp (COST), sold 700 shares on April 1, 2026, for $993.00 apiece, a transaction totaling $695,100. The shares are trading at $996.56 and are up 15.72% year-to-date, while InvestingPro flags the stock as overvalued relative to its Fair Value. Multiple analysts have reiterated their views as…
Fernando Austin Pena, president of Blackstone Mortgage Trust (NYSE: BXMT), sold 1,666 shares of Class A common stock on March 31, 2026, under pre-arranged Rule 10b5-1 plans to meet tax obligations tied to restricted stock vesting. The company recently reported fourth-quarter 2025 GAAP net income per share and a reduction in its CECL reserve. Keefe,…
Eagle Point Credit Management LLC sold 1,095 shares of ACRES Commercial Realty Corp’s 7.875% Series D Preferred Stock on March 30, 2026, for a weighted average of $22.12 per share, totaling $24,221. The transaction reduced but did not eliminate Eagle Point’s significant preferred and common holdings amid ACRES’s disappointing fourth-quarter 2025 ea…
Sempra Executive Vice President Justin Christopher Bird sold 1,128 shares on April 1, 2026, for $96.69 per share, generating proceeds of $109,066. The transaction occurred while the stock trades close to its 52-week high of $98.45. After the sale, Bird holds 21,631.51 shares directly and 4,722.09 shares indirectly through a 401(k) savings plan. The…
Director James Aloysius Brady sold 10,834 shares of Xeris Biopharma Holdings Inc on March 30, 2026 under a Rule 10b5-1 plan for $60,035. The company recently reported a fourth-quarter 2025 earnings and revenue beat and retains analyst interest, with price targets ranging from $8 to $18 and Barclays reiterating an Overweight rating with a $9 target.
Richard D. Gebert, a director at Independence Realty Trust, INC. (NYSE: IRT), sold 500 shares on April 1, 2026 through a Form 4 filing. The transaction, executed under a pre-arranged 10b5-1(c) trading plan, totaled $7,425. The sale coincides with IRT trading near its 52-week low and follows the REIT's mixed fourth-quarter financial results and a qu…
Phillips 66 Executive Vice President and CFO Kevin J. Mitchell sold 15,629 shares of company stock on March 30, 2026, for $2.97 million and simultaneously exercised options to acquire the same number of shares. The transactions leave Mitchell with 97,376 directly held shares and a smaller indirect stake through the COP Savings Plan. The moves coinc…
Mari Steinmetz, Kohl’s Senior Executive Vice President and Chief People Officer, completed automated sales of 1,954 Kohl’s shares on March 31 and April 1, 2026, totaling about $25,383. The transactions were made under a Rule 10b5-1 trading plan adopted November 26, 2025. Around the same dates she was awarded 33,091 shares under the company’s long-t…
Gevo, Inc. President and COO Christopher Michael Ryan sold 129,797 shares across two days under a previously established 10b5-1 plan, reducing but not materially changing his direct stake. The transactions coincided with the stock trading close to its 52-week high, amid a quarter that delivered sharply higher revenue yet continued operating losses.…
Paula Soteropoulos, a director at Dianthus Therapeutics, sold 599 shares on March 31, 2026, at $80.11 per share for $47,985 and concurrently exercised options to acquire 599 shares at $8.44 per share. The stock has since risen to $84.54 and trades close to an InvestingPro-tracked 52-week high of $88.49 after a 402% gain over the past year. The tran…
Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, sold $9.5 million of company stock on March 31, 2026, and exercised options to acquire additional shares the same day. The transactions occurred under a Rule 10b5-1 plan adopted in late December 2025. Separately, Dianthus completed a public offering that generated roughly $719 million in gross…
David Young, President of Research & Development at Processa Pharmaceuticals, purchased 1,810 shares of the company on March 31, 2026, for $2.535 per share, a $4,588 transaction. Following the purchase Young's direct holding rose to 10,562 shares, with additional indirect holdings across a trust, family entities, and an LLC. Processa, a small-cap b…
A Processa Pharmaceuticals director purchased 2,072 shares on March 31, 2026, for $2.535 each, adding $5,252 to her direct stake as the company progresses a Phase 2 study and shows mixed recent stock performance. The transaction was disclosed in a Form 4 filing and follows recent clinical enrollment milestones.
Processa Pharmaceuticals Chief Executive Officer George K Ng purchased 2,136 shares of the company on March 31, 2026, for a total of $5,414. The transaction increases his direct and indirect holdings. Separately, the company has completed enrollment and dosing of 20 patients for an interim analysis in its Phase 2 study of NGC-Cap in advanced or met…
Brent W. Clum, Co-CEO and CFO of TXO Partners, L.P. (NASDAQ: TXO), sold 27,234 common units on April 1, 2026, at $12.38 per unit, generating proceeds of $337,156. After the transaction he holds 800,340 common units. The partnership has seen a year-to-date stock gain of 20.76% and is flagged as undervalued by InvestingPro, offering a 9.54% dividend …
Processa Pharmaceuticals Chief Financial Officer Russell Skibsted purchased 2,324 shares of the company on March 31, 2026, spending $5,891 at $2.535 per share. The trade was reported on a Form 4 and leaves Skibsted with direct ownership of those shares. The stock is trading at $2.60 with analysts setting a price target of $25, per InvestingPro data…
Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, acquired 1,603 shares of common stock on March 31, 2026, a purchase valued at $4,063. The transaction leaves Lin with 3,356 shares directly and 1,740 shares indirectly via the Lin Family Trust Feb 4, 2024. Separately, Processa has finished enrollment and dosing for a planne…
